Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) have received an average rating of “Buy” from the six ...

Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shareholders might understandably be very concerned that the share ...

Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Capricor Therapeutics in a research ...

The consensus price target hints at a 208.1% upside potential for Capricor (CAPR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

The exosome therapies market is expected to experience significant growth due to increased interest in regenerative medicine, cancer treatments, and drug delivery systems. Leading Indications ...

Gene therapy-related stocks are poised to end the session in the green, riding high after Sarepta 's (SRPT +7.1%) bullish news yesterday.Seleted tickers: (SLDB -18.6%)(FCSC... BySeeking Alpha ...

Capricor Therapeutics (CAPR) closed the last trading session at $13.47, gaining 7.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

Capricor Therapeutics (CAPR) announced the completion of the submission of its Biologics License Application, BLA, to the U.S. Food and Drug ...

Ratings for Capricor Therapeutics (NASDAQ:CAPR) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Capricor Therapeutics (CAPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating ...